Evaxion Biotech A/S - ADR

NASDAQ:EVAX   3:59:50 PM EDT
1.92
-0.07 (-3.52%)
Products, Other Pre-Announcement

Evaxion Expands EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

Published: 06/23/2022 11:41 GMT
Evaxion Biotech A/S - ADR (EVAX) - Evaxion Biotech Expands Its Evx-03 Dna Vaccine Program Into Non-small Cell Lung Cancer.
Evaxion Biotech -selected Evx-03 As Product Candidate Within Its Dna Technology Platform to Target New Indication With Planned Regulatory Filing in H2.
Evaxion Biotech - Decided to Continue Development of Evx-03 in Patients With Advanced Disease and Plans to Target Nsclc With Evx-03.